IL10 and cardiovascular disorder: Based on the synergistic activity of VitD and Dexa to induce IL-10 and promote Tregs (28, 29), we recently postulated and demonstrated that a subcutaneous (sc) repetitive microdose delivery (REMID) strategy of a combined VitD/Dexa formulation increased the number of IL-10-producing leukocytes, reduced the Th1 proinflammatory response and attenuated the progression of atherosclerotic lesions (30), the major underlying cause of cardiovascular disease (CVD).